Similarly, the rate of abrogating mutations of BRG1 in colon and breast cancers is (0.0%) [1.28%] and (0.71%) [0.39%], respectively, while BRG1 is silenced in >25% of these cancers as determined by IHC (Table 2A). This evidence concerns the gene SMARCA4 and breast cancer.